Kobo Biotech Ltd

Kobo Biotech Ltd Share Price Today: Live Updates & Key Insights

Get insights on Kobo Biotech Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Kobo Biotech Ltd Share Price Chart

Kobo Biotech Ltd Fundamentals

Traded Volume: null

Market Cap(Cr): null

Avg Traded Price null

1 Year return %

Upper Circuit null

Lower Circuit null

P/E TTM 0.00

P/B Ratio 0.00

Traded Value(Cr) null

EPS TTM NaN

Book value NaN

Dividend null%

Kobo Biotech Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Kobo Biotech Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Kobo Biotech Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W null%

1M null%

3M null%

1Y null%

YTD null%

Kobo Biotech Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Kobo Biotech Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday null

Day Before Yesterday null

1W Avg null

1M Avg null

3M Avg null

Kobo Biotech Ltd Technical Details

Kobo Biotech Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 null

Support 2 null

Support 3 null

Pivot Point : null

Resistance 1 null

Resistance 2 null

Resistance 3 null

Kobo Biotech Ltd Corporate Actions

Kobo Biotech Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Kobo Biotech Ltd’s capital allocation strategies.

All

Dividends

No Dividend has been declared by null

Bonus

No Bonus has been declared by null

Splits

No Split has been declared by null

Others

Rights No Rights has been declared by null

Kobo Biotech Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Kobo Biotech Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Kobo Biotech Ltd's relative performance and valuation against major competitors.

Kobo Biotech Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Kobo Biotech Ltd, across its operating activities, investing activities, and financing activities.

Kobo Biotech Ltd Shareholding Pattern

This shows the ownership breakdown of Kobo Biotech Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter null%

Public null%

Other Institutions null%

FII null%

Mutual Funds null%

About Kobo Biotech Ltd

Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992. Effective 19th October, 2020, the Company`s name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited. The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company`s 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US. XTP shall be the technical supervisor for the transfer of technology, while SMEC shall supply the technical knowhow. The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSI-RAB for the manufacturing and marketing MMAA, MMAE, DEA, EEAA and Aralydes. The company had developed technology for recovery of Diketene from sludge. The company has also diversified into Bio-Technology, where the value addition is high. To part finance its biotech project the company has made a preferential issue of 1800000 Equity shares at Rs. 38.75 each aggregating to Rs. 697.50 lacs and issued 400000 warrants convertible into 400000 equity shares during the year 1999-2000. The Bio-Technology Plant is located at Solapur,Maharashtra for manufacture of Ephedrine and Pseudo-Ephedrine with an installed capacity of 150 MT p.a. The plant has commenced operations during April 2001. The biotech division produces Pharmaceutical intermediates i.e Pseudoephedrine and ephedrine. The company has signed two longterm export contracts to supply fixed quantities of Pseudoephedrine and is in talks with a few more MNC`s for long term contracts during the year 2001-02. The company`s bio-tech division is pursuing USFD approval which will enable it to enter into regulated markets. The company is all set to introduce two high value added intermediates in its Diketene Division.The company has already completed trial production for these two pharmaceutical products and is ready for commercial launch.The company is expected an additional turnover of Rs.12 crores from these products from the year 2005-06. During the year 2004-05, the Company increased its production capacity in Biotech Division. Further the company has increased the storage capacity of molasses from 2000 tons to 6000 tons. The Company in 2006-07 had received USFDA approval for its facilities at Biotech Division, at Solapur, Maharashtra for manufacture of Psuedoephedrine. Pursuant to the preferential issue of 98,09,100 equity shares [43.60% of the total paid-up equity share capital] of the Company to Arch Pharmalabs Limited in November, 2007, the SEBI [Substantial Acquisition of Shares and Takeovers] Regulations, 1997 were attracted and accordingly Arch Pharmalabs Limited, a Mumbai based Company engaged in business of manufacturing Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, was obligated to acquire upto 45,00,000 equity shares of Rs.10/- each representing 20% of the share capital of the Company. Further, on receipt of SEBI approval for the Open Offer vide SEBI letter dated 11th November, 2008, the Open Offer continued from 3rd December, 2008 till 22nd December, 2008. Pursuant to the closure of the Offer, 45,00,000 equity shares were accepted in the Open Offer at an offer price of Rs. 21.85 for each equity share and subsequently transferred to Arch Pharmalabs Limited, on 31 January, 2009. Post-transfer, the shareholding of Arch Pharmalabs Limited in the Company was 1,43,09,100 equity shares comprising 63.60% of the total equity capital of the Company. Pursuant to Arch Pharmalabs Limited acquiring a majority stake of 63.60% in the Company, the Company became a subsidiary of Arch Pharmalabs Limited. Regal Pharma PTE Ltd. was formed as wholly owned subsidiary company in Singapore on May 15, 2010.

Chairman (Non-Executive)

Ajit Kamath

Registered office Ground Flr D No 8-2-684/J/8/A, Bhavani Nagar Banjara Hills, Hyderabad, Telangana, 500034

FAX :null

Background

Incorporation Year 1993

Face Value ₹10.00

Market Lot 1

Kobo Biotech Ltd Latest News

VIEW MORE NEWS

FAQs on Kobo Biotech Ltd